Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab
作者： Carla Campanella , Marcella Mottolese , Anna Cianciulli , Angela Torsello , Roberta Merola
关键词:
摘要: Background Responsiveness to Cetuximab alone can be mediated by an increase of Epidermal Growth factor Receptor (EGFR) Gene Copy Number (GCN). Aim this study was assess the role EGFR-GCN in advanced colorectal cancer (CRC) patients receiving chemotherapy plus Cetuximab.
biomedcentral.com
springer.com
doaj.org
elsevier.com参考文章(32)
H Mellstedt, Monoclonal antibodies in human cancer. Drugs of Today. ,vol. 39, pp. 1- 16 ,(2003)
Robert B Diasio, Jeanne Fourie, Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. Drugs. ,vol. 66, pp. 1441- 1463 ,(2006) , 10.2165/00003495-200666110-00003
Leah N. Klapper, Mark H. Kirschbaum, Michael Seta, Yosef Yarden, Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors Advances in Cancer Research. ,vol. 77, pp. 25- 79 ,(1999) , 10.1016/S0065-230X(08)60784-8
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
Klaus Dittmann, Claus Mayer, Hans-Peter Rodemann, Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity Radiotherapy and Oncology. ,vol. 76, pp. 157- 161 ,(2005) , 10.1016/J.RADONC.2005.06.022
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Nicola Personeni, Steffen Fieuws, Hubert Piessevaux, Gert De Hertogh, Jef De Schutter, Bart Biesmans, Wendy De Roock, An Capoen, Maria Debiec-Rychter, Jean-Luc Van Laethem, Marc Peeters, Yves Humblet, Eric Van Cutsem, Sabine Tejpar, Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab : A fluorescent in situ hybridization study Clinical Cancer Research. ,vol. 14, pp. 5869- 5876 ,(2008) , 10.1158/1078-0432.CCR-08-0449
Mauro Moroni, Andrea Sartore-Bianchi, Silvio Veronese, Salvatore Siena, EGFR FISH in colorectal cancer: what is the current reality? Lancet Oncology. ,vol. 9, pp. 402- 403 ,(2008) , 10.1016/S1470-2045(08)70109-8
M. Peeters, T. Price, Y. Hotko, A. Cervantes, M. Ducreux, T. André, E. Chan, F. Lordick, A. Rong, J. Gansert, 14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC) Ejc Supplements. ,vol. 7, pp. 10- ,(2009) , 10.1016/S1359-6349(09)72049-X
J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M.E. Barugel, Y. Humblet, D. Cunningham, M. Wolf, J.L. Gansert, 10LBA Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial Ejc Supplements. ,vol. 7, pp. 6- ,(2009) , 10.1016/S1359-6349(09)72039-7